Natalizumab Agents (Tysabri, Tyruko)
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0020 alerts
Get alerted when Policy CC-0020 changes without checking for updates manually.
Monitor payer policy activity
Medical-necessity and prior-authorization coverage for Tysabri (natalizumab) and Tyruko (natalizumab-sztn) in adults with specified relapsing multiple sclerosis or moderately to severely active Crohn's disease, including Medicaid preferred-agent and step-therapy requirements.
ICD-10-CM code G37.9 was added for demyelinating disease of the central nervous system, unspecified, including clinically isolated syndromes.
ICD-10-CM code G35 was removed and replaced by G35.A and G35.C1 for relapsing-remitting and active secondary progressive multiple sclerosis.
Tyruko was added to the natalizumab clinical criteria and a quantity limit was added for natalizumab agents.
HCPCS Q5134 was added for Tyruko and HCPCS J3490 and J3590 were removed.
The policy history records step-therapy table updates on July 22, 2026 and May 1, 2026.
Ocrevus Zunovo was added to the exclusion for concurrent use with other disease-modifying therapy criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.